MX2020009966A - Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. - Google Patents
Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.Info
- Publication number
- MX2020009966A MX2020009966A MX2020009966A MX2020009966A MX2020009966A MX 2020009966 A MX2020009966 A MX 2020009966A MX 2020009966 A MX2020009966 A MX 2020009966A MX 2020009966 A MX2020009966 A MX 2020009966A MX 2020009966 A MX2020009966 A MX 2020009966A
- Authority
- MX
- Mexico
- Prior art keywords
- chlorokynurenine
- dosage forms
- therapeutic uses
- therapeutic
- compositions
- Prior art date
Links
- HQLHZNDJQSRKDT-QMMMGPOBSA-N (2s)-2-amino-4-(2-amino-4-chlorophenyl)-4-oxobutanoic acid Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=C(Cl)C=C1N HQLHZNDJQSRKDT-QMMMGPOBSA-N 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000009251 neurologic dysfunction Effects 0.000 abstract 1
- 208000015015 neurological dysfunction Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Lubricants (AREA)
- Quinoline Compounds (AREA)
Abstract
Se proporcionan composiciones L-4-cloroquinurenina, ya que son métodos para el tratamiento de disfunciones neurológicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361849191P | 2013-01-22 | 2013-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009966A true MX2020009966A (es) | 2020-10-12 |
Family
ID=51228003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015009277A MX375318B (es) | 2013-01-22 | 2014-01-22 | Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina.. |
| MX2020009966A MX2020009966A (es) | 2013-01-22 | 2015-07-17 | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015009277A MX375318B (es) | 2013-01-22 | 2014-01-22 | Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina.. |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US9993450B2 (es) |
| EP (4) | EP3228313B1 (es) |
| JP (5) | JP6436913B2 (es) |
| KR (5) | KR102335919B1 (es) |
| CN (4) | CN112933073A (es) |
| AU (5) | AU2014209466B2 (es) |
| BR (1) | BR112015017535A2 (es) |
| CA (3) | CA2898619C (es) |
| CY (1) | CY1122403T1 (es) |
| DK (3) | DK2948140T3 (es) |
| ES (3) | ES2635353T3 (es) |
| HK (1) | HK1217170A1 (es) |
| HR (2) | HRP20240812T1 (es) |
| HU (1) | HUE067381T2 (es) |
| IL (3) | IL291831A (es) |
| MX (2) | MX375318B (es) |
| PL (2) | PL3228313T3 (es) |
| PT (3) | PT2948140T (es) |
| RS (1) | RS59687B1 (es) |
| SI (2) | SI3228313T1 (es) |
| WO (1) | WO2014116739A1 (es) |
| ZA (2) | ZA201505569B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3228313T1 (sl) | 2013-01-22 | 2019-12-31 | Vistagen Therapeutics, Inc. | Odmerne oblike in terapevtske uporabe L-4-klorokinurenina |
| KR20240068766A (ko) * | 2015-05-22 | 2024-05-17 | 비스타젠 쎄라퓨틱스, 인크. | L-４-클로로키누레닌의 치료적 용도 |
| CA2996308A1 (en) * | 2015-09-08 | 2017-03-16 | Cephalon, Inc. | Prodrugs of chlorokynurenines |
| CN112236412B (zh) | 2018-02-09 | 2024-01-30 | 维斯塔津治疗公司 | 4-氯代犬尿氨酸及中间体的合成 |
| CN109223785A (zh) * | 2018-10-29 | 2019-01-18 | 中国药科大学 | 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用 |
| WO2022082100A1 (en) * | 2020-10-16 | 2022-04-21 | Vistagen Therapeutics, Inc. | Cocrystals of l-4-chlorokynurenine, compositions and therapeutic uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| US5484814A (en) | 1991-02-28 | 1996-01-16 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| US5360814A (en) | 1991-02-28 | 1994-11-01 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| TW518218B (en) | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| WO2003015713A2 (en) | 2001-08-20 | 2003-02-27 | Maiken Nedergaard | Treatment of glial tumors with glutamate antagonists |
| WO2004022069A1 (en) | 2002-09-06 | 2004-03-18 | Durect Corporation | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear |
| US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| KR20090004950A (ko) | 2006-04-12 | 2009-01-12 | 프로비오드룩 아게 | 효소 억제제 |
| EP1903028A1 (en) * | 2006-09-22 | 2008-03-26 | Werner Tschollar | Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects |
| US8058243B2 (en) | 2006-10-13 | 2011-11-15 | Hsc Research And Development Limited Partnership | Method for treating a brain cancer with ifenprodil |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| WO2009135091A1 (en) * | 2008-04-30 | 2009-11-05 | Medivation Technologies, Inc. | Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions |
| US20110190347A1 (en) * | 2008-08-21 | 2011-08-04 | Richter Gedeon Nyrt. | Methods for treating neuropathic pain |
| DK2421519T3 (en) | 2009-04-23 | 2017-02-06 | Univ Zuerich | NMDA RECEPTOR BLOCKERS FOR THE TREATMENT OF SEAL CELL ANAEMS |
| CA2763551A1 (en) * | 2009-06-17 | 2010-12-23 | Targacept, Inc. | Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands |
| JPWO2011019072A1 (ja) | 2009-08-12 | 2013-01-17 | ヒューマン・メタボローム・テクノロジーズ株式会社 | うつ病のバイオマーカー、うつ病のバイオマーカーの測定法、コンピュータプログラム、及び記憶媒体 |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| EP2338873A1 (en) * | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
| ES2560676T3 (es) | 2010-06-15 | 2016-02-22 | Grünenthal GmbH | Combinación farmacéutica para el tratamiento del dolor |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| SI3228313T1 (sl) | 2013-01-22 | 2019-12-31 | Vistagen Therapeutics, Inc. | Odmerne oblike in terapevtske uporabe L-4-klorokinurenina |
| EP2970080A4 (en) | 2013-03-14 | 2017-01-18 | Vistagen Therapeutics, Inc. | Synthesis of chiral kynurenine compounds and intermediates |
| CN112321678A (zh) | 2013-10-28 | 2021-02-05 | 诺雷克斯股份有限公司 | Nmda受体调节剂及其前药、盐和用途 |
| KR20240068766A (ko) | 2015-05-22 | 2024-05-17 | 비스타젠 쎄라퓨틱스, 인크. | L-４-클로로키누레닌의 치료적 용도 |
-
2014
- 2014-01-22 SI SI201431410T patent/SI3228313T1/sl unknown
- 2014-01-22 KR KR1020217015432A patent/KR102335919B1/ko active Active
- 2014-01-22 ES ES14743570.5T patent/ES2635353T3/es active Active
- 2014-01-22 CN CN202110387961.2A patent/CN112933073A/zh active Pending
- 2014-01-22 EP EP17170079.2A patent/EP3228313B1/en active Active
- 2014-01-22 KR KR1020227044517A patent/KR20230003410A/ko not_active Ceased
- 2014-01-22 EP EP19196366.9A patent/EP3598971B1/en active Active
- 2014-01-22 WO PCT/US2014/012598 patent/WO2014116739A1/en not_active Ceased
- 2014-01-22 KR KR1020237021428A patent/KR20230098711A/ko not_active Ceased
- 2014-01-22 IL IL291831A patent/IL291831A/en unknown
- 2014-01-22 US US14/762,015 patent/US9993450B2/en active Active
- 2014-01-22 CA CA2898619A patent/CA2898619C/en active Active
- 2014-01-22 CN CN202110387953.8A patent/CN113209068A/zh active Pending
- 2014-01-22 CA CA3216579A patent/CA3216579A1/en active Pending
- 2014-01-22 DK DK14743570.5T patent/DK2948140T3/en active
- 2014-01-22 CA CA3128321A patent/CA3128321C/en active Active
- 2014-01-22 RS RS20191519A patent/RS59687B1/sr unknown
- 2014-01-22 PT PT147435705T patent/PT2948140T/pt unknown
- 2014-01-22 PT PT171700792T patent/PT3228313T/pt unknown
- 2014-01-22 KR KR1020217039478A patent/KR20210149905A/ko not_active Ceased
- 2014-01-22 PL PL17170079T patent/PL3228313T3/pl unknown
- 2014-01-22 PL PL19196366.9T patent/PL3598971T3/pl unknown
- 2014-01-22 ES ES17170079T patent/ES2751138T3/es active Active
- 2014-01-22 KR KR1020157022405A patent/KR102257284B1/ko active Active
- 2014-01-22 PT PT191963669T patent/PT3598971T/pt unknown
- 2014-01-22 HR HRP20240812TT patent/HRP20240812T1/hr unknown
- 2014-01-22 SI SI201432078T patent/SI3598971T1/sl unknown
- 2014-01-22 EP EP14743570.5A patent/EP2948140B1/en active Active
- 2014-01-22 CN CN201480010060.XA patent/CN105073108A/zh active Pending
- 2014-01-22 JP JP2015553921A patent/JP6436913B2/ja active Active
- 2014-01-22 MX MX2015009277A patent/MX375318B/es active IP Right Grant
- 2014-01-22 HU HUE19196366A patent/HUE067381T2/hu unknown
- 2014-01-22 DK DK17170079T patent/DK3228313T3/da active
- 2014-01-22 AU AU2014209466A patent/AU2014209466B2/en active Active
- 2014-01-22 BR BR112015017535A patent/BR112015017535A2/pt not_active IP Right Cessation
- 2014-01-22 ES ES19196366T patent/ES2980120T3/es active Active
- 2014-01-22 HK HK16105132.0A patent/HK1217170A1/zh unknown
- 2014-01-22 EP EP24164414.5A patent/EP4385563A3/en active Pending
- 2014-01-22 DK DK19196366.9T patent/DK3598971T3/da active
- 2014-01-22 CN CN202110384159.8A patent/CN113116877A/zh active Pending
-
2015
- 2015-07-17 MX MX2020009966A patent/MX2020009966A/es unknown
- 2015-07-22 IL IL240090A patent/IL240090B/en active IP Right Grant
- 2015-08-03 ZA ZA2015/05569A patent/ZA201505569B/en unknown
-
2016
- 2016-02-08 US US15/018,219 patent/US9993453B2/en active Active
- 2016-11-02 ZA ZA2016/07581A patent/ZA201607581B/en unknown
-
2018
- 2018-05-14 US US15/978,855 patent/US10632091B2/en active Active
- 2018-06-08 US US16/003,793 patent/US10617663B2/en active Active
- 2018-06-08 US US16/003,816 patent/US10980758B2/en active Active
- 2018-06-08 US US16/003,804 patent/US20180369180A1/en not_active Abandoned
- 2018-09-13 JP JP2018171786A patent/JP6804497B2/ja active Active
- 2018-10-26 AU AU2018253600A patent/AU2018253600B2/en active Active
-
2019
- 2019-11-27 CY CY20191101244T patent/CY1122403T1/el unknown
- 2019-12-04 HR HRP20192189TT patent/HRP20192189T1/hr unknown
-
2020
- 2020-07-01 AU AU2020204420A patent/AU2020204420A1/en not_active Abandoned
- 2020-07-03 JP JP2020115273A patent/JP7021298B2/ja active Active
- 2020-07-16 IL IL276126A patent/IL276126B/en unknown
-
2022
- 2022-02-03 JP JP2022015622A patent/JP2022070894A/ja active Pending
- 2022-06-21 US US17/845,105 patent/US12036198B2/en active Active
- 2022-08-22 AU AU2022221382A patent/AU2022221382B2/en active Active
-
2024
- 2024-02-27 JP JP2024027330A patent/JP2024069257A/ja active Pending
- 2024-03-21 US US18/611,908 patent/US20250161251A1/en active Pending
- 2024-12-18 AU AU2024278564A patent/AU2024278564A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004557B (en) | Modulatory polynucleotides | |
| PH12016500953A1 (en) | Tricyclic compounds as anticancer agents | |
| PH12016501139B1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MY187540A (en) | Compounds active towards bromodomains | |
| MX2015010921A (es) | Compuestos de carbazol utiles como inhibidores de bromodominio. | |
| TW201613901A (en) | New compounds | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| HK1216175A1 (zh) | 治療性化合物和組合物 | |
| PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MX2016014559A (es) | Compuestos para el tratamiento de cancer. | |
| PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
| PH12016501173A1 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| MX2016008150A (es) | Formulaciones de berberina y usos de las mismas. | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| MX2017006513A (es) | Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor. | |
| PH12015502564A1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
| EP2994156A4 (en) | Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity | |
| EA201590615A1 (ru) | Стимулирующие лактацию композиции на основе фосфатидилсерина | |
| NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
| PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
| HK1237265A1 (en) | Combination therapy compositions and methods for treating cancers |